Preventive cardiology
Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease

https://doi.org/10.1016/j.amjcard.2008.09.075Get rights and content

The aim of this study was to evaluate the efficacy and safety of ezetimibe 10 mg added to atorvastatin 20 mg compared with doubling atorvastatin to 40 mg in patients with hypercholesterolemia at moderately high risk for coronary heart disease who did not reach low-density lipoprotein (LDL) cholesterol levels <100 mg/dl with atorvastatin 20 mg. In this 6-week, multicenter, double-blind, randomized, parallel-group study, 196 patients treated with atorvastatin 20 mg received atorvastatin 20 mg plus ezetimibe 10 mg or atorvastatin 40 mg for 6 weeks. Adding ezetimibe 10 mg to atorvastatin 20 mg produced significantly greater reductions in LDL cholesterol than increasing atorvastatin to 40 mg (−31% vs −11%, p <0.001). Significantly greater reductions were also seen in non-high-density lipoprotein cholesterol, total cholesterol, and apolipoprotein B (p <0.001). Significantly more patients reached LDL cholesterol levels <100 mg/dl with atorvastatin 20 mg plus ezetimibe compared with atorvastatin 40 mg (84% vs 49%, p <0.001). The 2 treatment groups had comparable results for high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and high-sensitivity C-reactive protein. The incidences of clinical and laboratory adverse experiences were generally similar between groups. In conclusion, the addition of ezetimibe 10 mg to atorvastatin 20 mg was generally well tolerated and resulted in significantly greater lipid-lowering efficacy compared with doubling atorvastatin to 40 mg in patients with hypercholesterolemia at moderately high risk for coronary heart disease.

Section snippets

Methods

This study (Protocol 079) was a 6-week, multicenter, double-blind, randomized, parallel-group titration study in patients with hypercholesterolemia conducted in 72 sites in the United States (65 sites), Canada (4 sites), Austria (2 sites), and Costa Rica (1 site) from February 13, 2006, to January 17, 2008. The protocol was approved by appropriate institutional review boards, and all patients provided informed written consent.

Patients meeting the inclusion criteria were men and women aged 18 to

Results

The flow of participants through the study is summarized in Figure 1. There were generally no clinically meaningful differences in the distribution of baseline characteristics between treatment groups, including demographics, risk factors, and lipid values and ratios (Table 1, Table 2). Baseline demographics revealed that 60% of the patients were white, 26% multiracial (Hispanic or Latino), 55% men, and 74% aged <65 years.

The coadministration of ezetimibe 10 mg with atorvastatin 20 mg produced

Discussion

The primary objective of this study was to compare the LDL cholesterol–lowering efficacy of ezetimibe 10 mg added to atorvastatin 20 mg with that of the doubling of atorvastatin to 40 mg in patients with hypercholesterolemia at moderately high risk for coronary heart disease who had LDL cholesterol levels ≥100 mg/dl while taking atorvastatin 20 mg. In this study, the coadministration of ezetimibe with atorvastatin 20 mg resulted in significantly greater reductions in LDL cholesterol and better

Acknowledgments

We wish to thank Mary E. Hanson, PhD, of Merck & Company for critical review and Martha Vollmer, MA, of Merck & Company for editorial assistance on this report, although neither met all criteria for authorship.

References (14)

There are more references available in the full text version of this article.

Cited by (0)

This study was supported by Merck/Schering-Plough Pharmaceuticals, North Wales, Pennsylvania.

Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.

View full text